Cargando...
Development and prevalence of castration-resistant prostate cancer subtypes
BACKGROUND: Castration-resistant prostate cancer (CRPC) occurs when prostate cancer (CaP) progresses under therapy-induced castrate conditions. Several mechanisms have been proposed to explain this acquired resistance, many of which are driven by androgen receptor (AR). Recent findings, however, sub...
Gardado en:
| Publicado en: | Neoplasia |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Neoplasia Press
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7522286/ https://ncbi.nlm.nih.gov/pubmed/32980775 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2020.09.002 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|